Enobosarm (Ostarine) is intended to be used as first line therapy for the treatment of cachexia in patients with advanced non-small cell lung cancer (NSCLC) in combination with first line chemotherapy. If licensed, it would represent the first in a new class of drug for this patient group. Enobosarm is an oral, non-steroidal selective androgen receptor modulator (SARM).
NSCLC accounts for approximately 80% of all lung cancers. Cachexia is common in patients with NSCLC and approximately 50% of patients with advanced NSCLC have severe muscle loss. Cachexia impairs quality of life and response to therapy, increasing the morbidity and mortality of cancer patients.
The treatment approach for cachexia is multimodal and includes treatment of causes for decreased nutritional intake, evaluation of anti-neoplastic options to reduce the catabolic drive of cancer, nutritional therapy, use of corticosteroids and progestational agents, and non-drug treatment like nutritional counselling and physical training. Enobosarm is currently in two phase III clinical trials comparing its effect on physical function and lean body mass against placebo. This trial is expected to complete in second half of 2013.
Elranatamab is in clinical development for relapsed/refractory multiple myeloma (MM). MM is a rare, incurable cancer of the blood that develops from plasma cells in the bone marrow (the spongy tissue inside the inner part of some bones) where large amounts of abnormal plasma cells are produced and interfere with the production of red and …